Sepsis and precision medicine: The leading position of Greece.

The pandemic caused by the new coronavirus SARS-CoV-2 (Covid-19 disease) was the springboard for the emergence of the Greek Sepsis Study Group as a protagonist of international therapeutic developments in the treatment of patients with serious infections. On 16 December 2021, the European Medicines Agency authorized the use of the drug anakinra for the treatment of adults with COVID-19 pneumonia and a risk of progression to severe respiratory failure as evidenced by suPAR biomarker values of 6ng/ml or greater. Licensing is based on the results of the phase II and III SAVE and SAVE-MORE studies. The success becomes even greater if we consider that this is the first indication in the context of precision medicine that a major international regulatory body for infections has given so far.

This success indicates the path to be followed by our Group: to be the world leader in the treatment of sepsis with the application of precision medicine. For this purpose, the two-day event is not only aimed at providing scientific information on current scientific developments. Our goal is for all of us, doctors, nurses, biologists and pharmacists to learn how, united and using the principles that have brought us success, we will make our vision a reality: curing sepsis and improving the quality of life of our patients.

Download the Program in pdf